Investigating a new treatment for spinal cord injuries using a drug called VersaMab-101
Official title: Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment
Funded at Versapeutics INC · NIH-10697262 · Data updated 2026-11-12
This study is looking at a new drug called VersaMab-101 to see if it can help people with spinal cord injuries by promoting the healing of damaged nerves, which could improve movement and feeling.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versapeutics INC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | September 18, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $2,380,552 |
| NIH project number | 2R44NS120397-02 |
| Project ID | NIH-10697262 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced spinal cord injuries, particularly those with incomplete injuries who may benefit from nerve regeneration.
✕Less likely to help
Patients with complete spinal cord injuries or those who do not have the potential for nerve regeneration may not benefit from this research.
What this research studies
This research focuses on developing and testing a new drug, VersaMab-101, for treating spinal cord injuries (SCI). The approach involves understanding how this drug can help regenerate damaged nerve connections in the spinal cord, which is crucial for restoring movement and sensation. The study will assess the safety and effectiveness of the drug in preclinical models, aiming to overcome barriers that prevent nerve regrowth after injury. By targeting the mechanisms that inhibit recovery, the research seeks to provide a potential therapeutic option for individuals suffering from SCI.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves recovery and quality of life for patients with spinal cord injuries.
How similar studies have gone: While there have been various approaches to spinal cord injury treatment, this specific method using VersaMab-101 is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Versapeutics INC
San Diego, United States Active
Researchers
- Principal investigator: Sun, Miao — Versapeutics INC
- Study coordinator: Sun, Miao
Related research
Other NIH-funded projects on the same topics.
-
Corticospinal neurons and recovery of precise forelimb movement after spinal cord injury
This project studies how spine injuries change brain circuits and whether targeted rehabilitation helps restore precise forelimb movement.
-
How baclofen and spinal cord stimulation interact in people with spinal cord injury
This study looks at how a common antispasmodic medicine (baclofen) works together with spinal cord stimulation in people who have spinal cord injuries and live with spasticity.
-
Targeting spinal cord inflammation with a new HuR inhibitor to help SCI patients
A new treatment approach uses a small molecule to block a brain-spinal inflammation regulator (HuR) that drives harmful inflammation after spinal cord injury, aiming to lessen damage and pain for people with SCI.
-
From Neural Control of Movement to Treatments for Spinal Cord Injury
A patient-focused project aims to translate how brain signals control movement after spinal cord injury into new treatments that improve muscle function and reduce spasticity.
-
Polaris: a compact system to help motor recovery after spinal cord injury and stroke
A new, easy-to-use device called Polaris may help people with spinal cord injury, stroke, or other chronic conditions regain movement by guiding a specialized reflex-based therapy.
-
Predicting and Preventing Chronic Aspiration After Traumatic Cervical Spinal Cord Injury
This project looks at swallowing problems and chronic aspiration in adults with traumatic neck spine injuries to find patterns that could prevent serious lung complications.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.